[
    {
        "file_name": "IMMUNOMEDICSINC_08_07_2019-EX-10.1-PROMOTIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "The Parties shall comply, and Company shall cause the Sales Representatives and Other Company Employees to comply, with the provisions set forth on Schedule 6.2, which govern the reporting of adverse events/adverse drug reactions associated with the Product, Product quality complaints associated with adverse events and other information concerning the safety of the Product within the Territory.",
                "changed_text": "The Parties shall comply, and Company shall cause the Sales Representatives and Other Company Employees to comply, with the provisions set forth on Schedule 6.2, which are optional guidelines to be used at the discretion of both parties.",
                "explanation": "Moving the pharmacovigilance procedures—mandatory reporting of adverse events and product complaints—to a general compliance section significantly reduces its enforceability. It makes the mandatory procedure seem optional.",
                "contradicted_law": "FDA regulations and other pharmacovigilance requirements.",
                "location": "ARTICLE VI REGULATORY MATTERS, Section 6.2 Pharmacovigilance Procedures"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "Company represents and warrants that it has established, and covenants that it will maintain during the Term, a compliance program consistent with the Compliance Program Guidance for Pharmaceutical Manufacturers published by the Office of Inspector General, U.S. Department of Health and Human Services.",
                "changed_text": "Company represents and warrants that it may, at its own discretion, establish a compliance program.",
                "explanation": "Downgrading the mandatory compliance program to a discretionary measure undermines the integrity and enforceability of the compliance framework. This can potentially allow the company to claim that they do not have to follow HHS compliance.",
                "contradicted_law": "Office of Inspector General Compliance Program Guidance.",
                "location": "ARTICLE XI REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS, Section 11.6 Other Compliance Matters"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "This Agreement may be terminated by either Party in the event that the other Party commits a material breach of this Agreement and (a) such breach shall not have been cured within thirty (30) days after the giving of notice of such material breach, unless (i) the specific provision to which such breach relates expressly provides for a different period, or (ii) the Parties mutually agree in writing to an extension of such period (the \"Cure Period\"); or (b) such breach, by its nature, is not curable. Unless such breach in clause (a) is cured during the Cure Period, such termination will be effective immediately upon the expiration of the Cure Period without any further action or notice by the non-breaching Party. In the case of a breach in clause (b), such termination will be effective thirty (30) days following written notice of such breach being given to the breaching Party.",
                "changed_text": "This Agreement may only be terminated for the following reasons: (a) if both parties are in mutual agreement, or (b) at the sole discretion of the Board of Directors, should they choose to terminate it.",
                "explanation": "Eliminating the ability to terminate the contract for a 'material breach' makes it much harder to enforce. This restricts termination rights, moving it from breach-based to discretionary/agreement-based.",
                "contradicted_law": "Basic contract law principles regarding breach of contract.",
                "location": "ARTICLE VIII TERM AND TERMINATION, Section 8.1 Term; Termination"
            }
        ]
    }
]